GSAC
GelStat Corp.0.0003
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
382.64KP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-K
FY2007 results
Gelstat's FY2007 revenues cratered to $18,178 from $233,974 in 2006, reflecting limited marketing amid insolvency struggles, with Q4 showing no equity transactions or disclosed momentum. Operating loss narrowed to $1.0M from $1.8M, driven by slashed SG&A to $106K and zero R&D, yet net loss hit $1.1M after $43K interest, yielding ($0.04) diluted EPS on 25M shares. Cash dwindled to $1K by year-end, propped by $158K financing, while liabilities ballooned to $2.1M. No employees. Going concern in doubt without new capital.
10-Q
Q1 FY2007 results
Gelstat's Q1 2007 revenue plunged 88% y/y to $10,566 from $91,391, with gross profit holding at $10,509 after costs fell to $57; operating loss narrowed sharply to $171,684 from $548,981, thanks to SG&A dropping 91% to $17,193 while consulting and management fees hit $165,000. Net loss eased to $182,384 ($0.01 per share) versus $558,461 ($0.04), the gap due to $10,700 interest on notes. Cash dwindled to $4,123, with operating cash use at $3,664 and no capex for FCF; total debt stayed at $535,000 (6% notes, extended past 2005). Patents reached $25,780 after migraine patent issuance. Cash is perilously low. Legal settlements loom with noteholders.
10-Q
Q2 FY2007 results
Gelstat's Q2 2007 revenues plunged 96% y/y to $2,665 while gross profit turned razor-thin at $207, yet operating loss narrowed to $284k from $360k thanks to slashed expenses. YTD through June 30, 2007, sales fell 92% y/y to $13k but net loss halved to $477k versus $927k prior year, driven by consulting amortization offsetting the shortfall. Cash dwindled to $6k amid $71k operating burn, offset by $70k stock issuance; $535k notes payable at 6% loomed large with no revolver. Patent issued March 2007. Expenses burned cash. Legal overhangs from note disputes linger.
10-Q
Q3 FY2007 results
Gelstat's Q3 revenue plunged 94% y/y to $2,638 from $45,994, with nine-month sales down 92% to $15,869, reflecting limited marketing per MD&A. Gross margins held up while operating expenses dipped slightly to $333,207, narrowing the operating loss to $332,958 from $320,903; net loss widened modestly to $343,791 due to steady interest expense. Cash edged up to $27,067, buoyed by $148,500 in financing against $126,720 operating burn, yet total debt stood at $548,500 including overdue notes at 6-8%. Free cash flow not disclosed in the 10-Q. Patents carry $25,136 value. Litigation lingers with vendors and noteholders.
10-Q
Q1 FY2008 results
Gelstat eked out revenue growth to $10,883 in Q1 2008 ended March 31, up 3% y/y from $10,566 while trimming operating loss to $131,548 (down 23% y/y from $171,684) via lower consulting fees, yet net loss widened slightly to $142,348 on steady interest expense. Gross margins held firm near 98%. Cash burn eased to $4,050 (derived), offset by $5,500 in related-party notes at 8%, lifting cash to $2,611 against $2.2M current liabilities. Debt remains past due. No capex; FCF not disclosed in the 10-Q. Ongoing litigation burdens cash.
IPO
Website
Employees
Sector
Industry
BIOE
Bio Essence Corp.
0.05+0.00
FLGC
Flora Growth Corp.
8.84+0.39
GCAN
Greater Cannabis Co Inc.
0.08+0.00
GELS
Gelteq Limited
0.96+0.00
GSTK
Growth Stalk Holdings Corp
3.00+0.00
GTBIF
Green Thumb Industries Inc.
9.63+1.23
HYEX
HEALTHY EXTRACTS INC.
1.99-0.22
IGPK
Integrated Cannabis Solutions,
0.00+0.00
NTRR
Neutra Corp.
0.00+0.00
PLSH
Panacea Life Sciences Holdings,
0.09+0.00